Research programme: chitinase inhibitors - OncoArendi Therapeutics

Drug Profile

Research programme: chitinase inhibitors - OncoArendi Therapeutics

Alternative Names: AMCase inhibitors – OncoArendi Therapeutics; CHI3L1 modulators - OncoArendi Therapeutics; Chit1 modulators - OncoArendi Therapeutics; OATD 01

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yale University
  • Developer OncoArendi Therapeutics
  • Class Antiasthmatics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Chitinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 09 Oct 2017 OncoArendi Therapeutics receives approval from German Federal Institute for Drugs and Medical Devices for initiation of a phase I trial of OATD 01 in Asthma (In volunteers)
  • 09 Oct 2017 OncoArendi Therapeutics plans a multiple-ascending dose clinical trial of OATD-01 in 2018
  • 13 Oct 2015 OncoArendi Therapeutics plans a single-ascending dose phase I trial of OATD 01 for Asthma (In volunteers) in Germany in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top